S Patel1, S H Chung2, G White3, S Bao2, D S Celermajer4. 1. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Discipline of Medicine, University of Sydney, Sydney, Australia; Discipline of Pathology, Bosch Institute, University of Sydney, Sydney, Australia. Electronic address: sanjay.patel@bigpond.com. 2. Discipline of Pathology, Bosch Institute, University of Sydney, Sydney, Australia. 3. Department of Vascular Surgery, Royal Prince Alfred Hospital, Sydney, Australia; Discipline of Surgery, University of Sydney, Sydney, Australia. 4. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Discipline of Medicine, University of Sydney, Sydney, Australia.
Abstract
OBJECTIVE: Inflammation is important in plaque vulnerability but the role of atheroprotective mediators in unstable plaques is not defined. The apolipoproteinA-I (apoA-I) component of HDL, and CD4+/CD25+ regulatory T cells (with their major transcription factor, Foxp3), have been implicated in the suppression of vascular inflammation. Our aim was to characterise the presence of these novel "protective" markers (apoA-I and Foxp3) in carotid plaques from symptomatic and asymptomatic subjects. METHODS AND RESULTS: Plaques from 57 patients (25 symptomatic, 32 asymptomatic) were stained immunohistochemically for macrophages (CD68), T cells (CD3), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-2 (MMP-2), myeloperoxidase (MPO), apoA-I and Foxp3. Twelve randomly selected plaques (6 asymptomatic, 6 symptomatic) were immunostained for interleukin-10 (IL-10) and interleukin-17 (IL-17). Staining was quantified using Image-Pro Plus software. Significantly greater areas of positive immunostaining for CD68, CD3, MCP-1, MMP-2, IL-17 and MPO were found in plaques from symptomatic patients compared with asymptomatic patients (p<0.05 for all). Furthermore, significantly greater areas of positive immunostaining for apoA-I, Foxp3 and IL-10 were found in symptomatic versus asymptomatic plaques (p<0.05 for all). The presence of apoA-I was correlated significantly and co-localised with CD3, CD68, MCP-1, MMP-2 and MPO immunostaining (R=0.70, 0.63, 0.52, 0.55 and 0.79, respectively; p<0.01 for all). Foxp3 immunostaining also correlated significantly with CD3 (R=0.42), CD68 (R=0.47), MCP-1 (R=0.55) and MMP-2 (R=0.44) immunostaining (p<0.05 for all). CONCLUSIONS: ApoA-I and Foxp3 are over-abundant in plaques from symptomatic subjects and co-localise with key inflammatory mediators. These data suggest ineffective/insufficient protection against atherosclerosis-mediated inflammation by these "atheroprotective" moieties. Crown
OBJECTIVE:Inflammation is important in plaque vulnerability but the role of atheroprotective mediators in unstable plaques is not defined. The apolipoproteinA-I (apoA-I) component of HDL, and CD4+/CD25+ regulatory T cells (with their major transcription factor, Foxp3), have been implicated in the suppression of vascular inflammation. Our aim was to characterise the presence of these novel "protective" markers (apoA-I and Foxp3) in carotid plaques from symptomatic and asymptomatic subjects. METHODS AND RESULTS: Plaques from 57 patients (25 symptomatic, 32 asymptomatic) were stained immunohistochemically for macrophages (CD68), T cells (CD3), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-2 (MMP-2), myeloperoxidase (MPO), apoA-I and Foxp3. Twelve randomly selected plaques (6 asymptomatic, 6 symptomatic) were immunostained for interleukin-10 (IL-10) and interleukin-17 (IL-17). Staining was quantified using Image-Pro Plus software. Significantly greater areas of positive immunostaining for CD68, CD3, MCP-1, MMP-2, IL-17 and MPO were found in plaques from symptomatic patients compared with asymptomatic patients (p<0.05 for all). Furthermore, significantly greater areas of positive immunostaining for apoA-I, Foxp3 and IL-10 were found in symptomatic versus asymptomatic plaques (p<0.05 for all). The presence of apoA-I was correlated significantly and co-localised with CD3, CD68, MCP-1, MMP-2 and MPO immunostaining (R=0.70, 0.63, 0.52, 0.55 and 0.79, respectively; p<0.01 for all). Foxp3 immunostaining also correlated significantly with CD3 (R=0.42), CD68 (R=0.47), MCP-1 (R=0.55) and MMP-2 (R=0.44) immunostaining (p<0.05 for all). CONCLUSIONS:ApoA-I and Foxp3 are over-abundant in plaques from symptomatic subjects and co-localise with key inflammatory mediators. These data suggest ineffective/insufficient protection against atherosclerosis-mediated inflammation by these "atheroprotective" moieties. Crown
Authors: Khoa D Nguyen; Claudia Macaubas; Kari C Nadeau; Phi Truong; Taejin Yoon; Tzielan Lee; Jane L Park; Elizabeth D Mellins Journal: Blood Date: 2011-02-16 Impact factor: 22.113
Authors: Jun Yang; Xiaoyang Yuan; Caixia Lv; Rong Bai; Le Zhang; Lei Ruang; Cuntai Zhang; Xiao-Qing Quan Journal: Am J Transl Res Date: 2016-12-15 Impact factor: 4.060
Authors: Madhurima Das; Christopher J Wilson; Xiaohu Mei; Thomas E Wales; John R Engen; Olga Gursky Journal: J Mol Biol Date: 2015-11-10 Impact factor: 5.469